The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases. The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk fu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Honigberg, Lee A., Smith, Ashley M., Sirisawad, Mint, Verner, Erik, Loury, David, Chang, Betty, Li, Shyr, Pan, Zhengying, Thamm, Douglas H., Miller, Richard A., Buggy, Joseph J.
Formato: Artigo
Lenguaje:Inglês
Publicado: National Academy of Sciences 2010
Materias:
Biological Sciences
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2919935/
https://ncbi.nlm.nih.gov/pubmed/20615965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1004594107
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares